Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Elan To Spin-Off Discovery Unit | Contract Pharma

What are you searching for?

Sign in
Breaking News

Elan To Spin-Off Discovery Unit

Creates Neotope discovery and translation business

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan plans to spin-off of its discovery sciences unit from the main company. The transaction will create two independent public companies, Elan Corp. plc and Neotope Biosciences plc. Subject to certain conditions, the spin-offs will be complete by the end of 2012.
 
Elan Corp. will initially consist of three main assets: Tysabri (marketed in collaboration with Biogen Idec) for Multiple Sclerosis and other potential indications; ELND005, a small molecule in Phase II for a range of neuropsychiatry and symptomatic diseases; and the continued interest in Janssen AI, under which Pfizer manages the on-going AIP portfolio including Phase II Bapineuzumab (subQ); Phase II vaccine (ACC-001) and Phase I AAB-003 (mab). Neotope Biosciences will continue to focus on identifying and translating targets into potential therapies for chronic degenerative and other related disease areas.
 
A joint statement from chairman Robert A. Ingram and chief executive officer Kelly Martin noted, “This is a bold and logical strategic step as it provides shareholders with the ability to delineate risk, timelines and business characteristics to their own specific investment objectives. As we have done over the past decade and will continue to do in the future, the strengthening of the balance sheet, capital structure, income statement and progression of the science for the benefit of patients, has been a constant goal and objective of the management team and supported by the board of directors.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics